Drug Discovery.

Humanized.

Javelin Biotech humanizes preclinical drug discovery with a predictive platform that merges human tissue chips and digital twin technology to develop better medicines faster.

NEXT GENERATION IN VITRO PHARMACOLOGY

Mechanistic understanding of the interactions between drugs and human physiology is essential for developing safe and efficacious therapies. As therapeutic modalities increase, current preclinical testing models become inadequate.  The lack of human-specificity of animal models and the limited complexity of current in vitro models result in an increase to preclinical drug discovery costs and risk of clinical attritions.

Javelin human tissue chips bring both human complexity and specificity for acute and chronic drug studies. The chips generate longitudinal, high-content, and human-relevant data. Javelin AI-enabled digital twin technology analyzes multi-modal chip data and translates to human responses to design better medicines faster.

THE JAVELIN PLATFORM

  • Expand mechanistic understanding of drug-organ interactions

  • Avoid inter-species differences

  • Develop better medicines faster